NASDAQ:MRTX - Mirati Therapeutics Stock Price, Forecast & News

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Mirati Therapeutics Inc (NASDAQ:MRTX) released its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts' consensus estimates of ($1.25) by $0.13. The biotechnology company had revenue of $0.99 million for the quarter, compared to analyst estimates of $0.50 million. Mirati Therapeutics had a negative return on equity of 48.60% and a negative net margin of 2,698.66%. View Mirati Therapeutics' Earnings History.

Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Mirati Therapeutics.

16 brokers have issued 1 year price objectives for Mirati Therapeutics' shares. Their forecasts range from $81.00 to $134.00. On average, they expect Mirati Therapeutics' stock price to reach $107.93 in the next year. This suggests a possible upside of 11.6% from the stock's current price. View Analyst Price Targets for Mirati Therapeutics.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics.

News headlines about MRTX stock have trended somewhat positive on Tuesday, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mirati Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Mirati Therapeutics.

Some companies that are related to Mirati Therapeutics include Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY) and ACADIA Pharmaceuticals (ACAD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include AbbVie (ABBV), Arrowhead Pharmaceuticals (ARWR), Exelixis (EXEL), Netflix (NFLX), NVIDIA (NVDA), Viking Therapeutics (VKTX), Bausch Health Companies (BHC), Amarin (AMRN), Micron Technology (MU) and Tandem Diabetes Care (TNDM).

Mirati Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (8.12%), FMR LLC (5.11%), Janus Henderson Group PLC (4.96%), Sands Capital Management LLC (4.57%), State Street Corp (3.13%) and Lord Abbett & CO. LLC (1.82%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Jamie Christensen, Michael G Grey and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.

MRTX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Pictet Asset Management Ltd., Farallon Capital Management LLC, Schonfeld Strategic Advisors LLC, State Street Corp, Driehaus Capital Management LLC and Credit Suisse AG. Company insiders that have sold Mirati Therapeutics company stock in the last year include Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Jamie A Donadio, Michael G Grey and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

MRTX stock was purchased by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Lord Abbett & CO. LLC, Eagle Asset Management Inc., Amundi Pioneer Asset Management Inc., UBS Asset Management Americas Inc., Sofinnova Investments Inc., Victory Capital Management Inc. and Victory Capital Management Inc.. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MRTX stock can currently be purchased for approximately $96.72.

Mirati Therapeutics has a market capitalization of $3.81 billion and generates $12.93 million in revenue each year. The biotechnology company earns $-98,420,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.View Additional Information About Mirati Therapeutics.

The official website for Mirati Therapeutics is http://www.mirati.com/.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]